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INTRODUCTION
Systematic neonatal screening has been progres-
sively implemented in industrialized countries over the
past 2 decades. Screening programs for congenital hy-
pothyroidism (CH) have also been expanding through-
out South America and developing countries, where se-
vere mental deficiency from CH has clearly been re-
duced.1 The vast majority of programs are now using a
primary thyroxine (T
4
)-backup thyrotrophin  (TSH) or a
primary TSH test.2 In Brazil, cord blood evaluation has
been recommended, particularly because of the short
hospital stay of our normal pregnant women.3 Also, TSH
has been recommended as the primary screening test
because it detects not only permanent sporadic con-
genital hypothyroidism, whose incidence is about 1 per
3500-4000 births in our region, but also compensated
or transient primary hypothyroidism, whose incidence
can be as high as 1 in 10 neonates and whose main
cause is iodine deficiency.3-6 There is some evidence that
our region is deficient in iodine supplementation.7,8
However, T
4
 primary screening programs have still been
carried out and are widely preferred in many assistance
centers in Brazil. Although there have been some pre-
vious studies on the perinatal factors influencing TSH
and T
4
 concentrations in cord blood, particularly in high-
risk newborns, those small for gestational age and/or
preterm infants, there is still poor knowledge about the
possible influence of severe maternal diseases over sen-
sitive TSH measurement methods. The aim of the
present work was to investigate the influence of non-
thyroidal mothers’ diseases on our routine screening
program using primary cord TSH values.
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abstract
CONTEXT: Screening programs not only offer the opportunity to trace
and treat almost all cases of congenital hypothyroidism but also
mean large savings to the health system. However, carefully planned
strategies are necessary to extend their benefits and reduce costs.
OBJECTIVE: To determine the possible influence of maternal diseases
that affect maternal-fetal placenta dynamics on primary thyroid stimu-
lating hormone (TSH) screening for congenital hypothyroidism.
DESIGN: Prospective non-randomized clinical trial with at least 3
months of follow-up.
SETTING: A public university referral center [CAISM/Hospital das
Clínicas, Faculty of Medicine, University of Campinas, Campinas, SP].
PARTICIPANTS: 415 neonates divided into 5 groups: eighty-three
infants born from cardiac mothers; 98 from mothers that had tox-
emia; 54 of the mothers had diabetes mellitus; 40 were HIV positive
and 140 had no diseases.
INTERVENTION: All newborns had cord blood samples collected
on filter paper at birth.
MAIN MEASUREMENTS: TSH was measured from dried blood spots
using a homemade immunofluorescence assay (sensitivity in dried
blood spots = 0.1 mU/L).
RESULTS: There was no significant difference in the mean TSH levels
among the 5 groups. Moreover, TSH levels were around 5 mU/L in
48% of the newborns, indicating that our region is severely deficient
in iodine.
CONCLUSIONS: Our results indicate that primary TSH screening
programs using cord blood are not affected by maternal diseases.
We suggest that, besides its technical advantages over heel punc-
tures with T4 primary approaches, neonatal screening using primary
cord blood TSH may also be used as a monitoring tool for evalua-
tion and control of iodine deficiency disorders (IDD).
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METHODS
The procedures that follow were in accordance
with the ethical standards of the committee respon-
sible for human experimentation and with the Helsinki
declaration of 1975, as revised in 1983.
Setting
A public university referral center, the Center for
Integrated Assistance in Women’s Health at the Uni-
versity of Campinas - Centro de Assistência Integrada
à Saúde da Mulher/Hospital das Clínicas da Faculdade
de Medicina da Universidade de Campinas, Campinas.
Design
Prospective non-randomized clinical trial with
at least 3 months follow-up.
Participants
We examined and enrolled a minimum of 415 new-
borns from the Maternity Department of the University
of Campinas (CAISM/UNICAMP). In accordance with their
mothers’ profiles, they were divided into 5 groups:
Group A. Composed of 83 infants of mothers with
congestive cardiac diseases, including Chagas’ dis-
ease, hypertensive cardiac disease, and valve disease.
They were divided into Functional Type II (n = 23 pa-
tients), Functional Type III (n = 39) and Functional Type
IV (n = 21), according to the criteria committee of the
New York Heart Association.9
Group B. Composed of 98 infants from mothers with
toxemic pregnancies classified as moderate (diastolic blood
pressure < 10 mmHg; n = 72 patients) or severe (diastolic
blood pressure > 10 mmHg; n = 26 patients).
Group C. Composed of 54 infants from diabetic
mothers, classified into type A (n = 30), type B (n =
13) and type C (n = 11), according to the Priscilla White
classification.10
Group D. Composed of 40 infants from mothers
Table 1. Thyroid stimulating hormone  (TSH) levels in
mU/L, expressed as mean and standard deviation, of
infants of group A: cardiac disease mothers (n = 83);
group B: toxemic mothers (n = 98); group C: diabetic
mothers (n = 54); group D: HIV positive mothers; group
E: control healthy mothers (n = 140). Group C is sub-
divided into Priscilla White classes A (n = 30),
B (n = 13) and C (n = 11). Statistical comparison
revealed no difference among groups (P > 0.05)
Groups Thyroid stimulating hormone
Mean SD
A 6.51 3.58
B 6.13 4.85
C 6.08 4.76
Class A 6.43 4.58
Class B 6.94 3.98
Class C 6.04 4.15
D 6.42 4.10
E 6.42 4.10
Figure 1.  Percentile distribution of TSH levels for the 5 different groups of
infants born from: group A: toxemic mothers (N = 98); group B: diabetic
mothers N = 54); group C: cardiac disease mothers (N = 83) ; group D: HIV
positive mothers and group E: control healthy mothers (N = 140). P > 0.05.
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infected by the human immunodeficiency virus (HIV
positive) but with no active disease.
Group E. A control group of 140 normal preg-
nant women.
Diagnostic test
Cord blood samples were collected by labor-room
personnel. TSH concentrations were measured in 2-3 out
of 5 cord blood spots collected on filter paper, using a
homemade immunofluorescence assay described else-
where.11 The detection limit of the assay in dried blood
spots is 0.1 mU/L and in plasma is 0.05 mU/L, with inter
and intra-assay coefficients of variation of 5 and 10%, re-
spectively. T
4
 was also measured with a fluorometric as-
say with a sensitivity of 1.6 mg/dL, with inter and intra-
assay coefficients of variation of 5 and 10%, respectively.
Statistical Methods
Computer statistical programs, EPIINFO and
STATGRAG, Microsoft 5.0, were used for analyzing data.
Duncan, Ryan-Einot-Gabriel Welsh, chi-square (χ2),
Kruskal-Wallis (H) and ANOVA (F) tests were used to
verify differences between groups and subgroups. Re-
sults were expressed as the mean ± standard deviation
(SD). The level of significance was taken as P < 0.05.
RESULTS
The infant’s sex, duration of labor, mode of deliv-
ery and use of uterogenic agents were similar in all groups
(χ2 = NS). Table 1 represents TSH mean levels, expressed
as the mean and standard deviation, in patients of the 5
groups. In Figure 1, these data are expressed as their
percentile distribution in each of the 5 groups.
Comparison of these results shows no statistical
difference among groups or subgroups (H = 0.4963; P =
0.29; F = 0.609, P = 0.65). All values were below our cut-off
value for congenital hypothyroidism (20 mU/L). No child
demonstrated any feature that could be suspected as con-
genital hypothyroidism during a follow-up of, at least, 3
months (mean 5 months, SD 2). Forty-eight percent of
the newborns presented a TSH cord blood level above 5
mU/L. There was no statistical difference in the distribu-
tion of TSH > 5 mU/L cases in the different groups.
DISCUSSION
Clinical diagnosis of congenital hypothyroidism
is difficult at birth and measurements of TSH are essen-
tial for this diagnosis. A screening program not only of-
fers the opportunity to trace and treat almost all cases
but also means large savings to the country.12 However,
to extend the benefits of screening programs and reduce
costs, carefully planned strategies are necessary. The
Brazilian Endocrine Society recommends a primary TSH,
T
4
 back-up program on cord blood samples. However, T
4
has still been defended as the ideal method by many
services that also use heel puncture performed at the
3rd to 5th day of life. We have previously demonstrated
that, although both strategies are able to detect all cases
of hypothyroidism, umbilical cord blood is technically
superior to heel puncture and primary TSH clearly re-
duces the recall index for confirmation of the results.13
Infants born prior to term have lower cord serum
T
4
 concentrations that correlate with gestational age or
birth weight.14 Previous reports have shown that other
factors, like maternal diseases affecting placental dynam-
ics, may influence T
4
 values and thus the screening pro-
grams that use primary T
4
.15,16 However, data on the pos-
sible influence of these factors on cord blood TSH are
scarce. Franklin, et al. analyzed the effects of maternal
diabetes mellitus, toxemia, fetal distress and other fac-
tors and concluded that they did not affect cord serum
TSH concentrations.15 Only the delivery method influ-
enced cord serum T
4
. Another early report from Fuse, et
al. also suggested that TSH values in cord blood could
be less influenced by perinatal factors than T
4
 values.16
We investigated newborns from mothers affected by se-
vere non-thyroidal diseases, including HIV. Our data con-
firm that even severe maternal diseases do not affect a
screening program using primary TSH from cord blood.
The World Health Organization (WHO), United
Nations International Children’s Emergency Fund
(UNICEF), and the International Council for Control of
Iodine Deficiency Disorders (ICCIDD) have included
neonatal TSH as one of the indicators for assessing io-
dine deficiency disorders (IDD) and their control.6 In
the absence of iodine deficiency, the frequency of neo-
natal TSH above 5 mU/L whole blood (or 10 mU/L se-
rum) is less than 3%. A frequency of 3-19.9% indicates
mild IDD. Frequencies of 20-39.9% and above 40% indi-
cate moderate and severe IDD, respectively. We found
a 48% prevalence of TSH cases above 5 mU/L indicat-
ing that our region is severely deficient in iodine. Re-
cently Haddow et al suggested that maternal thyroid
dysfunction during pregnancy may impair the subse-
quent neuropsychological development in children,
raising our concerns about iodine supplementation.8,17
We suggest that, besides its technical advan-
tages over heel punctures with T
4
 primary approaches,
neonatal screening using primary cord blood TSH may
also be used as a monitoring tool for IDD evaluation
and control in Brazil.
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resumo
CONTEXTO: Os programas de detecção precoce trazem economias
ao sistema de saúde e oferecem a oportunidade de rastrear e tratar
precocemente casos de hipotiroidismo congênito.
OBJETIVO: Determinar influências de doenças que afetam a dinâmica ma-
terno-fetal-placentária sobre programas de detecção precoce de hipotiroi-
dismo congênito que se baseiam na dosagem do hormônio tirotrófico (TSH).
TIPO DE ESTUDO: Ensaio clínico prospectivo não-randomizado com,
ao menos, três meses de seguimento.
LOCAL: Centro Universitário Público de Referência - Centro de Atendimento
Integrado a Saúde da Mulher (CAISM).
PARTICIPANTES: 415 recém-nascidos de 5 grupos de parturientes:
83 crianças eram filhas de mães cardiopatas; 98 de mães com
toxemia gravídica; 54 de mães diabéticas; 40 de mães portadoras
de imunodeficiência adquirida (HIV); e 140 de mães hígidas.
PROCEDIMENTOS: Todos os recém-nascidos tiveram amostras de
sangue de cordão umbilical coletadas em papel de filtro ao nascimento.
VARIÁVEIS ESTUDADAS: Dosagem de TSH em sangue coletado
em papel de filtro usando um ensaio imunofluorométrico próprio
(sensibilidade em manchas de sangue seco = 0.1 mU/L).
RESULTADOS: Não encontramos diferença na média de TSH dos 5 grupos.
Além disso, os níveis de TSH estavam acima de 5 mU/L em 48% dos
bebês, sugerindo que nossa região é severamente deficiente em iodo.
CONCLUSÕES: Nossos resultados demonstram que programas de
detecção precoce de hipotiroidismo congênito, que utilizam primariamente
TSH, não são afetados por doenças maternas não-tiroidianas. Sugerimos
que, além das vantagens técnicas sobre a punção de calcanhar com
dosagem primária de T4, os programas de detecção precoce que utilizam
primariamente TSH de cordão umbilical também podem ser usados como
instrumento de avaliação e controle da carências de iodo.
PALAVRAS-CHAVE: Hipotiroidismo congênito. Rastreamento.
Doença materna.
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